Piper Sandler analyst Joseph Catanzaro reiterated a Buy rating on Exelixis (EXEL – Research Report) today and set a price target of $28.00. The company’s shares closed yesterday at $21.83.
Catanzaro covers the Healthcare sector, focusing on stocks such as Exelixis, Gilead Sciences, and Nurix Therapeutics. According to TipRanks, Catanzaro has an average return of 6.5% and a 41.75% success rate on recommended stocks.
Exelixis has an analyst consensus of Strong Buy, with a price target consensus of $27.07, a 24.00% upside from current levels. In a report released today, RBC Capital also reiterated a Buy rating on the stock with a $28.00 price target.
See the top stocks recommended by analysts >>
EXEL market cap is currently $6.65B and has a P/E ratio of 33.90.
Based on the recent corporate insider activity of 78 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exelixis (EXEL) Company Description:
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
Read More on EXEL:
- Cybrexa regains rights to CBX-12
- EXEL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Exelixis price target raised to $25 from $24 at Barclays
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Exelixis announces results of study evaluating cabozantinib in mCRPC treatment
